“According to preliminary expert data, the turnover of this vaccine on the world market is estimated at about $ 100 billion, an annual turnover.
This is good business.
And the humanitarian component is absolutely bright, and it is in demand, ”RIA Novosti quotes him.
Earlier, the director of the Gamaleya Center, Alexander Gintsburg, spoke about the queue of companies wishing to produce and sell the Russian Sputnik V coronavirus vaccine.
On October 21, Gunzburg gave a forecast on the production volumes of the Russian Sputnik V coronavirus vaccine.